Publikationen (80) Publikationen von José María López-Picazo González

2024

  1. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  2. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

    The Journal of experimental medicine, Vol. 219, Núm. 12

2021

  1. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

    Oral Oncology, Vol. 115

  2. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

2020

  1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  2. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program

    Clinical and Translational Oncology, Vol. 21, Núm. 9, pp. 1270-1279

  3. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

  4. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2825-2834

  5. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

  2. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

  3. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

  4. Targeted DNA sequencing for assessing clonality in multiple lung tumors: A new approach to an old dilemma

    Lung Cancer, Vol. 122, pp. 120-123

2017

  1. Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer

    Hospital practice (1995), Vol. 45, Núm. 3, pp. 70-75

  2. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. Bringing model-based prediction to oncology clinical practice: A review of Pharmacometrics principles and applications

    Oncologist, Vol. 21, Núm. 2, pp. 220-232

  2. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694